MOUNTAIN VIEW, Calif., Sept. 16 /PRNewswire/ -- Aviron (Nasdaq: AVIR),
today announced that it has filed a shelf S-3 Registration Statement with the
Securities and Exchange Commission pursuant to which it may offer up to an
aggregate of $100 million of securities from time to time in one or more
transactions. No underwriters are involved in the shelf registration.
Net proceeds from the sale of any such securities will be used to fund
operating costs, capital expenditures and working capital needs, which may
include costs of FluMist(TM) regulatory filings and the manufacturing and
commercialization of FluMist(TM) in its current formulation; development of a
second-generation formulation of FluMist(TM); research and development of
other pipeline products; development of the infrastructure necessary to
support these activities; and other general corporate purposes.
Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.
A written prospectus, when available, meeting the requirements of Section
10 of the Securities Act of 1933 may be obtained from Aviron at 297 North
Bernardo Avenue, Mountain View, California 94043.
A registration statement relating to these securities has been filed with
the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted prior to
the time the registration statement becomes effective. This news release
shall not constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any State in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such State.
This press release contains forward-looking statements. Actual results
may differ materially from the forward-looking statements contained in this
release. Factors that could cause actual results to differ include, but are
not limited to, failure to demonstrate stability or failure to validate the
manufacturing process for the Company's nasal influenza vaccine, and the
assessment by regulatory agencies that the Company's future license
applications for its nasal influenza vaccine are incomplete or inadequate to
approve the product for marketing to one or more target populations.
Additional information concerning factors that could cause such a difference
is contained in Aviron's SEC filings, including its shelf S-3 Registration
Statement, Annual Report on Form 10-K for the year ended December 31, 1998,
and subsequent Forms 10-Q.
To receive an index and copies of recent press releases, call Aviron's
News-On-Call toll-free fax service, 800-758-5804, extension 114000.
Additional information about the company can be located at
http://www.aviron.com.
SOURCE Aviron
 back to top
Related links:
http://www.aviron.com
Company News On-Call:
http://www.prnewswire.com/comp/114000.html or fax,
800-758-5804, ext. 114000
CONTACT:
media, Karen Gilbert, 650-919-6578, or
investors, John Bluth, 650-919-3716, or Fred Kurland,
650-919-6666, all of Aviron; or Louise Leavitt of
Fleishman-Hillard, 212-453-2000, for Aviron
|
